INSIGHTS ON CLINICAL TRIAL DESIGN

• Change Needed In Approach To Clinical Trials Patient Recruitment

  Drawing on real-world experience and end-to-end capabilities, this presentation outlines actionable strategies to accelerate recruitment, boost predictability, and expand patient trial access.

• The Story Behind MIDBA: An Exclusive Interview - Ypsomed

  A new regulatory framework reduces PK bridging study needs, helping sponsors streamline device transitions, lower costs, speed up timelines, and boost regulatory predictability for combination products.

• Protocol Design Choices That Trigger IRB And Regulatory Requirements

  Learn how protocol choices like AI, adaptive designs, and decentralized methods impact IRB review, participant protections, consent, and key regulatory requirements in clinical research.

• Expanding Clinical Research In East Africa With Digital Innovation

  Africa carries 25% of the world’s disease burden but hosts only 1% of clinical trials. Discover technology-driven strategies that close this gap and transform research access in underserved regions.

• Rethinking Trial Access Through Trust-Driven Design And Local Collaboration

  5/19/2026

  Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.

• Why Site Engagement Belongs At Investigators' Meetings

  8/4/2026

  Investigators’ meetings are a great opportunity to give sites direct access to the teams supporting patient travel and reimbursement, clarify available services early, and surface practical needs before they become study barriers.

• ADCs In Oncology Trials Webinar

  10/2/2025

  Whether you are preparing to launch your first ADC study or looking to optimize current programs, this session will deliver practical insights you can put into action immediately.

• Inclusive Trial Design A 'Must-Have' In Modern R&D

  8/14/2025

  Inclusivity in trial design is a crucial aspect of the R&D process, recognized for its importance to ensuring scientific validity, ethical responsibility, and public health.

• Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems

  10/7/2025

  Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.